FEP 7.01.96 Computer-Assisted Musculoskeletal Surgical Navigational Orthopedic Procedure

Effective Policy Date: July 1, 2020
Original Policy Date: December 2011

Related Policies:
None

Computer-Assisted Musculoskeletal Surgical Navigational Orthopedic Procedure

Description

Computer-assisted navigation in orthopedic procedures describes the use of computer-enabled tracking systems to facilitate alignment in a variety of surgical procedures, including fixation of fractures, ligament reconstruction, osteotomy, tumor resection, preparation of the bone for joint arthroplasty, and verification of the intended implant placement.

OBJECTIVE

The objective of this evidence review is to determine whether the use of computer-assisted navigation improves the net health outcome when used for orthopedic procedures, including ligament reconstruction, surgery for trauma or fracture, hip arthroplasty, periacetabular osteotomy, and total knee arthroplasty.

POLICY STATEMENT

Computer-assisted surgery for orthopedic procedures of the pelvis and appendicular skeleton is considered investigational.
POLICY GUIDELINES

None.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

Reimbursement for the technical component of computer-assisted navigation may be sought through the use of the CPT codes or through hospital case rates.

FDA REGULATORY STATUS

Because computer assisted navigation is a surgical information system in which the surgeon is only acting on the information that is provided by the navigation system, surgical navigation systems generally are subject only to 510(k) clearances from the U.S. Food and Drug Administration (FDA). As such, the FDA does not require data documenting the intermediate or final health outcomes associated with computer assisted navigation. (In contrast, robotic procedures, in which the actual surgery is robotically performed, are subject to the more rigorous requirement of the premarket approval application process.)

A variety of surgical navigation procedures have been cleared for marketing by the FDA through the 510(k) process with broad labeled indications. For example, The OEC FluoroTrak 9800 plus is marketed for locating anatomic structures anywhere on the human body.

Several navigation systems (eg, PiGalileo™ Computer-Assisted Orthopedic Surgery System, PLUS Orthopedics; OrthoPilot Navigation System, Braun; Navitrack Navigation System, ORTHOsoft) have received the FDA clearance specifically for total knee arthroscopy. The FDA cleared indications for the PiGalileo™ system are representative. This system "is intended to be used in computer-assisted orthopedic surgery to aid the surgeon with bone cuts and implant positioning during joint replacement. It provides information to the surgeon that is used to place surgical instruments during surgery using anatomical landmarks and other data specifically obtained intraoperatively (eg, ligament tension, limb alignment). Examples of some surgical procedures include but are not limited to:

- Total knee replacement supporting both bone referencing and ligament balancing techniques
- Minimally invasive total knee replacement."

FDA product code: HAW.

In 2013, the VERASENSE™ Knee System (OrthoSensor) and the iASSIST™ Knee (Zimmer) were cleared for marketing by the FDA through the 510(k) process. FDA product codes: ONN, OLO.

Several computer-assisted navigation devices cleared by the FDA are listed in the table below.

Table 1. Computer-Assisted Navigation Devices Cleared by the U.S. Food and Drug Administration

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>Date Cleared</th>
<th>510(k) No.</th>
<th>Indication</th>
</tr>
</thead>
</table>

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
### RATIONALE

#### Summary of Evidence

For individuals who are undergoing orthopedic surgery for trauma or fracture and receive computer-assisted navigation, the evidence includes one retrospective clinical trial, reviews, and in vitro studies. Relevant outcomes are symptoms, morbid events, and functional outcomes. Functional outcomes were not included in the clinical trial, although it did note fewer complications with computer-assisted navigation versus conventional methods. The evidence is insufficient to determine the effects of the technology on net health outcomes.

For individuals who are undergoing ligament reconstruction and receive computer-assisted navigation, the evidence includes a systematic review of 5 randomized controlled trials (RCTs) of computer-assisted navigation versus conventional surgery for anterior and posterior cruciate ligament. Relevant outcomes are symptoms, morbid events, and functional outcomes. Trial results showed no consistent improvement of tunnel placement with computer-assisted navigation, and no trials looked at functional outcomes or need for revision surgery with computer-assisted navigation. The evidence is insufficient to determine the effects of the technology on net health outcomes.

For individuals who are undergoing hip arthroplasty and periacetabular osteotomy and receive computer-assisted navigation, the evidence includes older RCTs, a systematic review, and comparison studies. Relevant outcomes are symptoms, morbid events, and functional outcomes.

---

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.
functional outcomes. Evidence on the relative benefits of computer-assisted navigation with conventional or minimally invasive total hip arthroscopy is inconsistent, and more recent RCTs are lacking. The evidence is insufficient to determine the effects of the technology on net health outcomes.

For individuals who are undergoing total knee arthroscopy and receive computer-assisted navigation, the evidence includes RCTs, systematic reviews of RCTs, and comparative studies. Relevant outcomes are symptoms, morbid events, and functional outcomes. The main difference found between total knee arthroscopy with computer-assisted navigation and total knee arthroscopy without computer-assisted navigation is increased surgical time with computer-assisted navigation. Few differences in clinical and functional outcomes were seen at up to 10 years post-procedure. The evidence is insufficient to determine the effects of the technology on net health outcomes.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

No guidelines or statements were identified.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

REFERENCES


The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.


BOARD OF DIRECTORS

1. New Policy

December 2011

New Policy

Policy statement changed to "not medically necessary".

June 2012

Replace Policy

Policy updated with literature search; references 6, 9, 14, 16, 19, 21-23, 25-27, and 32 added; policy statement unchanged.

September 2013

Replace Policy

Policy updated with literature review through November 7, 2016; references 7, 12, 21, 24, 26 and 32 added; some references removed. Title changed to "Computer-Assisted Navigation for Orthopedic Procedure". Policy statement unchanged except "not medically necessary" corrected to "investigational" due to FDA 510(k) clearance.

March 2017

Replace Policy

Policy updated with literature review through February 5, 2018; no references added. Policy statement unchanged.

June 2018

Replace Policy

Policy updated with literature review through February 4, 2019; references added. Policy statement unchanged.

June 2019

Replace Policy

Policy updated with literature review through February 11, 2020; no references added. Policy statements unchanged.

June 2020

Replace Policy

Policy updated with literature review through February 11, 2020; no references added. Policy statements unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.